COO

Business Context and Reporting Period

Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 30, 1998 (Six months ended April 30, 1998)
Business Overview: The Company develops, manufactures, and markets healthcare products, including contact lenses (CooperVision) and surgical instruments (CooperSurgical), and provides healthcare services through psychiatric facilities (Hospital Group of America).

Key Financial Metrics

Note: All figures in thousands except per share data and percentages.

Material Changes vs. Prior Period

• Revenue Growth: Net operating revenue increased 52% year-over-year to $94.6 million. Product sales rose 77% and service revenue rose 14%.
• Profitability: Net income increased 67% to $14.5 million, driven by a $5.1 million increase in operating income.
• Acquisition Impact: The December 1997 acquisition of Aspect Vision Care Limited ("Aspect") was the primary driver of growth, contributing significantly to product sales and operating income. Aspect accounted for 55% of product sales growth in the six-month period.
• Margin Compression: Consolidated product gross margin decreased from 70% to 64%. This was attributed to the acquisition of Aspect (lower margin products) and increased sales of lower-margin Natural Touch products.
• Liquidity and Debt: Total debt surged from $9.6 million to $71.5 million to finance acquisitions (Aspect, Litmus, Hyskon). Cash and cash equivalents declined from $18.2 million to $1.5 million due to significant investing outflows ($42.3 million) and negative operating cash flow.

Guidance, Outlook, Risks, and Unusual Items

Management Commentary and Outlook

• Product Launches: CooperVision introduced "Frequency 55" disposable lenses and new toric products. CooperSurgical launched the "Cerveillance Scope" and "FemExam" diagnostic tests.
• Cash Flow: Management expects cash flow from operations to fund ongoing operations, though additional financing may be required for European plant expansions or future acquisitions.
• Year 2000: The Company estimates the total cost of Year 2000 compliance will not be material.

Risks and Contingencies

• Pending Litigation (GT Labs): A jury awarded $1.7 million in damages for breach of contract regarding contact lens blanks. The Company intends to appeal the liability findings and verdict.
• Pending Litigation (Russo Securities): Plaintiffs seek over $9.8 million in compensatory damages and over $10 million in punitive damages related to alleged fraud and misrepresentations concerning debenture resets. The Company denies the claims and intends to vigorously defend.
• Environmental: Groundwater contamination (TCA) identified at a CooperVision site. The Company has accrued $510,000 total for remediation and does not expect costs to be material.
• Foreign Exchange: Significant debt is denominated in Pounds Sterling. The Company uses forward currency contracts to hedge exposure.

Investor Verification Checklist

• Debt Servicing: Verify the Company's ability to service the new $71.5 million debt load, particularly the $27.8 million Aspect promissory notes and $17.4 million Midland Bank loan.
• Acquisition Integration: Monitor the integration of Aspect Vision Care and the realization of expected synergies in European and North American markets.
• Litigation Outcomes: Track the status of the GT Labs appeal and the Russo Securities lawsuit, as adverse rulings could impact financial position.
• Liquidity Position: Assess the low cash balance ($1.5 million) relative to current liabilities ($45.5 million) and the reliance on the $50 million KeyBank revolver.
• Margin Trends: Watch for further margin compression or improvement as the product mix shifts toward new proprietary products.